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Recent studies have identified stem cells in
brain cancer. However, their relationship to
normal CNS progenitors, including dependence
on common lineage-restricted pathways, is un-
clear. We observe expression of the CNS-re-
stricted transcription factor, OLIG2, in human
glioma stem and progenitor cells reminiscent
of type C transit-amplifying cells in germinal
zones of the adult brain. Olig2 function is
required for proliferation of neural progenitors
and for glioma formation in a genetically rele-
vant murine model. Moreover, we show
p21WAF1/CIP1, a tumor suppressor and inhibitor
of stem cell proliferation, is directly repressed
by OLIG2 in neural progenitors and gliomas.
Our findings identify an Olig2-regulated line-
age-restricted pathway critical for proliferation
of normal and tumorigenic CNS stem cells.
INTRODUCTION
Investigation of highly tumorigenic cellular subpopulations
in adult primary tumors has revealed fundamental similar-
ities to normal stem and progenitor cells within the same
lineage (Garraway and Sellers, 2006). Such findings sup-
port the proposition that proliferation and survival of tumor
cells may be dependent on the same ‘‘lineage-restricted’’Nepathways that govern early phases of organogenesis.
However, this concept remains to be functionally tested
in a broad range of solid cancers, and potential interac-
tions between such lineage-restricted regulatory factors
and classical tumor suppressors are poorly understood.
From a developmental perspective, the regulatory net-
works controlling stem cell behavior in the vertebrate brain
are relatively well characterized. Primary cancers of the
brain, therefore, provide a favorable context in which to
consider the conserved features of normal and tumori-
genic stem cells. The most common form of primary brain
cancer is the malignant glioma, ‘‘primary glioblastoma’’
(astrocytoma, WHO Grade IV) (Louis et al., 2002). These
uniformly fatal cancers are characterized by stereotypical
combinations of genetic lesions, commonly involving am-
plification/activation of the epidermal growth factor recep-
tor (EGFR) and loss-of-function mutations in the retino-
blastoma (Rb) signaling axis for cell cycle control (Louis
et al., 2002; Maher et al., 2001). At a histopathological
level, primary glioblastomas consist of a heterogeneous
mixture of cell types with some evidence of multilineage
differentiation. Recent work has identified cells with
stem-like features in glioblastoma (Bao et al., 2006; Galli
et al., 2004; Singh et al., 2004; Vescovi et al., 2006). The
varied appearance of these tumors has led to proposals
that the ‘‘cell of origin’’ is either a developmentally arrested
neural stem cell or else a committed progenitor cell that
has dedifferentiated to a more stem-like state (Kesari
and Stiles, 2006).
Two cell populations that promote glioma growth have
been identified. Rapidly cycling glioma progenitor cells,uron 53, 503–517, February 15, 2007 ª2007 Elsevier Inc. 503
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Olig2 Is Required in Glioma Progenitorswhich express the proliferation marker Ki67, and generally
comprise less than 30 percent of tumor cells. Even less
frequent within the tumor is a highly tumorigenic subpop-
ulation of glioma stem cells identifiable by the stem/pro-
genitor cell marker CD133 (Bao et al., 2006; Singh et al.,
2004). These two replication competent cell populations
invite comparisons to progenitors in the subventricular
zone (SVZ) of the normal adult brain (Sanai et al., 2005).
In this stem cell niche, relatively quiescent ‘‘type B’’ neural
stem cells give rise to rapidly dividing ‘‘type C’’ progenitor
cells (Doetsch et al., 1999).
During central nervous system (CNS) development, the
bHLH transcriptional repressor proteins Olig1 and Olig2
play essential roles in the lineage specification of progen-
itor cells into neuronal subtypes (somatic motor neurons
and forebrain cholinergic neurons) and oligodendrocytes
(Furusho et al., 2006; Hack et al., 2005; Lu et al., 2002;
Mizuguchi et al., 2001; Novitch et al., 2001; Takebayashi
et al., 2002; Zhou and Anderson, 2002). At early embryonic
stages, one key role of Olig2 is to maintain progenitor cells
in a replication-competent state (Lee et al., 2005). The
structurally related Olig1 transcription factor is required
for maturation of oligodendrocyte progenitors (Arnett
et al., 2004; Xin et al., 2005). Although it is coexpressed
with Olig2 at early stages, Olig1 function is dispensable
for specification of neurons or oligodendrocytes from rep-
lication competent progenitor cells (Lu et al., 2002; Zhou
and Anderson, 2002).
Several lines of evidence suggest that the activity of
Olig2 might provide a mechanistic link between growth
of malignant glioma and adult neural stem cells. First, a
subpopulation of type B and type C cells in the adult ro-
dent brain express Olig2 (Bachoo et al., 2002; Hack
et al., 2005; Menn et al., 2006). Second, exposure to gli-
oma-relevant mitogens such as EGF or PDGF (Jackson
et al., 2006) stimulates proliferation of Olig2+ rapidly divid-
ing ‘‘type C’’ transit-amplifying cells and glioma-like
growths. Lastly, we and others have shown that all malig-
nant gliomas, irrespective of grade, express Olig2 in at
least some fraction of the malignant cell population (Azzar-
elli et al., 2004; Bouvier et al., 2003; Ligon et al., 2004; Lu
et al., 2001b; Marie et al., 2001; Ohnishi et al., 2003). Here,
we show that Olig2 function is required for glioma forma-
tion and that a common Olig2-dependent mechanism for
cell cycle control regulates growth of normal and malig-
nant neural progenitor cells.
RESULTS
OLIG2 Is Expressed in Human Glioma
Stem/Progenitor Cells
To determine whether OLIG2 might have a functional role
in tumorigenesis, we first examined whether OLIG2 is ex-
pressed in the specific cell types capable of contributing
to tumor growth. We quantitated glioma progenitor cells
by their expression of the proliferation marker Ki67 or
CD133, which has been proposed as a marker for glioma
stem cells (Bao et al., 2006; Singh et al., 2004). Immuno-504 Neuron 53, 503–517, February 15, 2007 ª2007 Elsevier Inchistochemical (IHC) colocalization of OLIG2 and Ki67
within human glioblastoma sections shows expression
of OLIG2 within at least 85% of Ki67+ glioma progenitor
cells by manual counting (n = 3 tumors; Figure 1A). Quan-
titative flow cytometry of fresh surgical glioblastoma spec-
imens (n = 11) shows that while Ki67+ cells represent a mi-
nority of the total OLIG2+ population (37%), the vast
majority (85%) of Ki67+ glioma progenitor cells are
OLIG2+ (Figures 1A–1C). In contrast, analysis of OLIG1 ex-
pression showed less correlation with cycling glioma pro-
genitor cells, as only 57% of Ki67+ cells expressed OLIG1
(Figure 1C).
Flow cytometry analysis of fresh human glioblastomas
(n = 11) shows that the CD133+ cells comprise only 6%
of the tumor; however, almost all (98%) of these are
OLIG2 positive (Figures 1D and 1E). In contrast, only 7%
of the CD133-positive cells express Olig1 (Figure 1E).
Taken together, these findings establish OLIG2 as
a marker expressed in two cell types that contribute to tu-
mor growth. However, as indicated in Figures 1C and 1E
and summarized in Figure 1F, OLIG2 expression is not
confined to glioma progenitors.
Olig2 Function Is Required for Glioma Formation
To determine whether Olig genes are required for glioma
formation, we used a murine model of malignant glioma
that emulates common genetic lesions underlying primary
glioblastoma in humans (Bachoo et al., 2002). In this
model, neural stem/progenitor cells from p16Ink4a/p19Arf
null mouse embryos are transformed with a retrovirus con-
taining a constitutively active mutation of epidermal
growth factor receptor (EGFRvIII) identified in human glio-
blastoma multiforme (GBM; Rasheed et al., 1999). The
resulting cells can be cultured as neurospheres capable
of glioma formation with 100% penetrance when trans-
planted into the brains of immunocompromised (SCID)
mice (Figure 2A). The tumors thus formed closely model
the neuropathological and immunophenotypic features
of human anaplastic astrocytoma WHO Grade III (Figure 3
and see Figure S1 in the Supplemental Data available with
this article online), including prominent expression of
Olig2, rapid growth, and marked single-cell infiltration of
normal brain structures. In this model, tumor cells can
be positively identified at single-cell resolution using hu-
man-specific antibodies to EGFR (hEGFR).
To remove Olig function in this model, we generated
neurospheres from compound transgenic mouse embryos
that were Ink4a/Arf null and either wild-type, heterozy-
gous, or null with respect to combined Olig1/2 function
(Zhou and Anderson, 2002; Figure 2A). We chose to initially
evaluate deletion of both Olig genes because both are ex-
pressed in malignant gliomas, and during development
they have partially redundant functions (Lu et al., 2002;
Zhou and Anderson, 2002). Analysis of survival cohorts
showed that all animals implanted with Olig1/2 wild-type
(n = 12) or heterozygous (n = 25) Ink4a/Arf/EGFRvIII neu-
rospheres developed neurological symptoms and died
within 100 days postinjection (dpi; Figure 2B; Table 1). In.
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Olig2 Is Required in Glioma ProgenitorsFigure 1. Human Glioma Progenitor Cells and Glioma Stem Cells Express OLIG2
(A) Immunohistochemistry for OLIG2 (red) and the proliferation marker, Ki67 (green) in a human glioblastoma. Arrows denote colocalization of proteins
(yellow) in glioma progenitor cells.
(B) Scatter plot showing flow cytometric analysis of Ki67 and OLIG2 in a human glioblastoma sample.
(C) Summary of flow cytometry results characterizing glioma progenitor cell populations in human glioblastomas (n = 11).
(D) Scatter plot showing flow cytometric analysis of CD133 and Olig2 in human glioblastoma sample.
(E) Summary of flow cytometry results characterizing CD133+ putative glioma stem cell populations in fresh human GBM with respect to OLIG2
(n = 11) and OLIG1 (n = 4) expression. All p values < 0.001. O1 = OLIG1, O2 = OLIG2. Error bars indicate SEM.
(F) Summary of the data shown in (C) and (E).striking contrast, 91% of the mice injected with Olig1/2-
null Ink4a/Arf/EGFRvIII neurospheres survived without
symptoms as long as 39 weeks postinjection (n = 23)
(Figure 2B; Table 1) and did not show evidence of tumor
growth in the brain (see below).These observations are consistent with requirements
for unique or overlapping functions of Olig2 and Olig1 in
glioma formation. To investigate the specific effects of
Olig2, we infected Olig1/2 null Ink4a/Arf/EGFRvIII neu-
rospheres with a retrovirus encoding full-length mouseFigure 2. Olig2 Is Required for Glioma
Formation from Neural Stem Cells
(A) Strategy for murine glioma model utilizing
genetically defined neural stem cells as the
cell of origin. 23 105 Ink4a/Arf/EGFRvIII neu-
rosphere cells of the indicated genotypes were
transplanted orthotopically into the striatum of
SCID mice and animals monitored for symp-
toms of glioma formation.
(B) Kaplan-Meier survival analysis. SCID mice
injected with Olig1/2+/ or Olig1/ Ink4a/
Arf/EGFRvIII neurospheres die from tumors
with short latency (median survival = 69 days
and 81 days, respectively) relative to mice in-
jected with Olig1/2 null Ink4a/Arf/EGFRvIII
neurospheres (96% survival at 273 days). Cen-
sored animals in the Olig1/2/ group (up ticks)
indicate noncancer deaths. P < 0.01 for Olig
1/2/ versus Olig1/ or Olig1/2+/.
(C) Kaplan-Meier survival analysis showing res-
toration of tumor phenotype in Olig-deficient
mice by Olig2 encoding retrovirus (orange) (me-
dian TFS = 132 days), but not control GFP virus
(purple) (100% survival at 136 days), p < 0.01.Neuron 53, 503–517, February 15, 2007 ª2007 Elsevier Inc. 505
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Olig2 Is Required in Glioma ProgenitorsFigure 3. Olig2 Is Required for Glioma
Growth but Not Neurosphere Engraft-
ment in the Brain
(A and D) H&E staining and hEGFR IHC on
coronal section of SCID mouse brain 100
days after injection with Olig1/2+/ Ink4a/
Arf/EGFRvIII neurospheres demonstrating
growth of malignant glioma.
(B and E) Tumor histologically resembles hu-
man anaplastic astrocytoma W.H.O. grade III
and uniformly expresses hEGFR.
(C and F) Single-cell infiltration of brain paren-
chyma is seen by H&E and hEGFR IHC. For ad-
ditional characterization see Figure S1.
(G and J) Age-matched brain injected with
Olig1/2/ TNS. Box indicates injection site.
(H) No tumor formation is detected by H&E
staining at site of injection (arrow).
(K) Rare surviving hEGFR+ Olig1/2/ Ink4a/
Arf/EGFRvIII neurospheres have morpholog-
ical characteristics of astrocytes (arrowhead)
and neurons (arrow).
(I and L) Subsequent infection of Olig1/2/
Ink4a/Arf/EGFRvIII neurospheres with Olig2
encoding retrovirus rescues formation of glio-
mas histologically identical to those from
Olig1/2+/ Ink4a/Arf/EGFRvIII neurospheres.Olig2 (Figure 2A). Exogenous production of Olig2 expres-
sion in Olig1/2 null Ink4a/Arf/EGFRvIII neurospheres ef-
fectively restores the tumorigenic phenotype (Figure 2C;
Table 1), albeit with slightly increased latency and re-
duced penetrance compared to Ink4a/Arf/EGFRvIII
neurospheres with intact Olig1/2 function. In addition,506 Neuron 53, 503–517, February 15, 2007 ª2007 Elsevier InInk4a/Arf/EGFRvIII neurospheres derived from single
knockout, Olig1 null donors demonstrated robust tumor
formation with 87% of animals (n = 10) developing fatal
tumors by 10 weeks postinjection (Figure 2B). Together,
these findings demonstrate that Olig2 function is specifi-
cally required for glioma formation. Further, they rule outTable 1. Survival Data Summary
Ink4a/Arf/EGFRvIII
Genotype
Total %
Developing
Tumors
# Tumor
Deaths/Total
# Animals
Total #
Independent
Lines
# Animals
in Survival
Cohorts
Median Tumor-Free
Survival
(Days)
Olig1/2+/+ 100 12/12 2 12 37
Olig1/2+/ 100 51/51 4 25 69
Olig1/2/ 9 4/45 4 23 n/d
Olig1/2/:GFP 0 0/8 2 8 n/d
Olig1/2/:Olig2 64 9/14 2 14 132
Olig1+/ 100 7/7 1 7 59
Olig1/ 94 16/17 2 10 81
Total animal counts combine data from survival cohorts and timed endpoint cohorts. Median tumor-free survival is calculated only
using animals in survival cohorts. Survival was 96% at 273 days for animals injected with Olig1/2/ Ink4a/Arf/EGFRvIII neuro-
spheres and 100% at 136 days for those injected with Olig1/2/:GFP-infected Ink4a/Arf/EGFRvIII neurospheres. In all experi-
ments, the presence of tumors was scored as positive for collections of atypical cells greater than 2 mm in diameter.c.
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Olig2 Is Required in Glioma ProgenitorsFigure 4. Olig2 Regulates the Growth
and Morphology of Ink4a/Arf/EGFRvIII
Neurospheres
(A) The mean viable cell number of Olig1/2/
Ink4a/Arf/EGFRvIII neurospheres is signifi-
cantly reduced compared to Olig1/2+/ con-
trols (p < 0.001).
(B) Partial restoration of Olig1/2/ Ink4a/
Arf/EGFRvIII neurosphere growth is seen
following infection with Olig2 retrovirus but
not with the GFP control (p < 0.05).
(C) Morphology of Olig1/2+/ Ink4a/Arf/
EGFRvIII neurospheres (Tumorigenic Neuro-
spheres, TNS) resembles that of normal neuro-
spheres.
(D) Olig1/2/ Ink4a/Arf/EGFRvIII neuro-
spheres exhibit marked adherence and migra-
tion on underlying substrate (arrow).
(E) Infection of Olig1/2/ Ink4a/Arf/EGFRvIII
neurospheres with Olig2 retrovirus completely
restores cells to the morphology of wild-type
Ink4a/Arf/EGFRvIII neurospheres. All neuro-
spheres were cultured under growth conditions
in the presence of EGF.
Error bars indicate SEM.the possibility that culturing of Ink4a/Arf/EGFRvIII
neurospheres from Olig1/2 null animals selects for Olig-
independent progenitors that are fundamentally incapable
of glioma formation.
Olig2 Regulates Proliferation and Morphology
of Tumorigenic Neurospheres
The intracranial tumors that form in this murine model of
malignant glioma can be readily visualized using human
specific EGFR antibodies. As indicated in Figures 3A–3F
and S1, these tumors closely recapitulate the neuropath-
ological and immunophenotypic features of human ana-
plastic astrocytoma WHO Grade III. In contrast, histopath-
ological analysis of Olig1/2 null Ink4a/Arf/EGFRvIII
neurosphere-injected animals at 70 dpi showed that
these cells survive and engraft in the brain but do not
form gliomas (Figures 3G, 3H, 3J, and 3K). They were
identified as scattered cells with differentiated astrocytic
and neuronal morphologies immediately surrounding the
injection site but with no evidence of mass-like growth
or tumor formation in nearly all (91%) cases (Table 1).
In vitro analysis to further investigate the effects of Olig
loss of function indicates that Olig1/2 null Ink4a/Arf/
EGFRvIII neurospheres are capable of proliferation, albeit
at a significantly lower rate than Olig1/2-heterozygous
cells (p < 0.001; Figure 4A). Olig1/2+/ Ink4a/Arf/
EGFRvIII neurospheres are tripotent (capable of express-
ing astrocyte, neuron, and oligodendrocyte markers in dif-
ferentiation conditions), whereas the Olig1/2/ Ink4a/
Arf/EGFRvIII neurospheres are bipotent, with evidence
of astrocytic and neuronal differentiation (Figure S2), as
expected based on known roles of Olig1/2 for oligoden-
drocyte specification in neurosphere cultures (Zhou and
Anderson, 2002). Moreover, the morphology of Olig1/2
null neurospheres is dramatically altered (Figures 4C andN4D). Relative to their wild-type counterparts, the Olig1/2-
null cells show increased adhesiveness and migration on
the culture dish. Cells lacking Olig function are eventually
unable to sustain growth as free-floating spheres and pro-
liferate instead as a partial monolayer (Figure 4D). The ab-
errant adhesion of Olig null Ink4a/Arf/EGFRvIII neuro-
spheres is of interest since monolayer culture is one of
the important external cues for differentiation of normal
neurosphere cultures (Reynolds and Weiss, 1992).
Interestingly, restoration of Olig2 activity in Olig null
Ink4a/Arf/EGFRvIII neurospheres by retroviral transduc-
tion restores wild-type growth and morphology in vivo (Fig-
ures 3I and 3L) and in vitro (Figures 4B and 4E). Therefore,
Olig2 regulates both the net proliferation and the histo-
pathological appearance of Ink4a/Arf/EGFRvIII neuro-
spheres in the brain. Loss of Olig2 function suppresses
tumor formation and promotes a more mature and differ-
entiated morphologic phenotype of the engrafted cells.
Olig2 Regulates Proliferation and Morphology
of Normal Neural Stem Cells
To better define the relationship between malignant and
normal neural stem cells, we examined Olig expression
in neural progenitor cells established from normal mice.
Proliferating cells in S phase were marked by a 2 hr pulse
of bromodeoxyuridine (BrdU). Subsequent immunohisto-
chemical analysis shows that Olig2 is expressed in the
majority (85%) of the cycling cells (Figure 5). In contrast,
relatively few of these cells express Olig1 (24%). The un-
coupling of Olig1 and Olig2 expression in these normal
neurospheres is reminiscent of that found in glioma stem
cells of human GBM (Figure 1C).
Analysis of the growth rates ofOlig1/2orOlig2null neural
progenitors demonstrates a significant reduction (2.2- and
1.6-fold, respectively) in growth for both genotypes relativeeuron 53, 503–517, February 15, 2007 ª2007 Elsevier Inc. 507
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Olig2 Is Required in Glioma ProgenitorsFigure 5. Olig Genes Regulate the Growth and Morphology of Normal Neurospheres
(A–D) Olig2 is highly expressed in undifferentiated and proliferative neurosphere cells.
(A) IHC showing widespread Olig2 expression (green) in a cultured neurosphere.
(B) IHC for BrdU.
(C) Merged image showing strong colocalization of Olig2 and BrdU.
(D) Manual quantitation of IHC colocalization results for Olig1 and Olig2 expression (p < 0.01).
(E) The mean viable cell number at various passages for Olig1/2/ or Olig2/ neurospheres was significantly lower than wild-type or heterozygous
counterparts (p < 0.001).
(F) The percentage of proliferating BrdU+ cells is significantly lower in the Olig1/2/ cultures relative to wild-type (p < 0.05).
(G) Cell death measured by Trypan blue staining is not significantly altered in the Olig1/2/ cultures compared to wild-type.
(H) Typical rounded morphology of wild-type neurospheres.
(I and J) Olig1/2/ and Olig2/ neurospheres are reduced in numbers and size. Spheres also show extensive adherence and migration on the sub-
strate (arrows). All neurospheres were derived from ganglionic eminences of wild-type or Olig mutant 14.5 dpc embryos and were cultured in the
presence of EGF.
Error bars indicate SEM.to heterozygous or wild-type controls (Figure 5E). In addi-
tion, Olig1/2 null neural stem cells show a marked reduc-
tion in the number of rapidly cycling cells in S phase as de-
termined by BrdU labeling (1.6-fold reduction; Figure 5F).
Cell death (as measured by Trypan blue exclusion) is not
affected by Olig status (Figure 5G). We observed that sin-
gle-cell suspensions of Olig1/2 null neurospheres are ca-
pable of self-renewal (data not shown). However, the mor-
phologic appearance of neurospheres is clearly regulated
by Olig status in a fashion similar to that noted for Ink4a/
Arf/EGFRvIII neurospheres (Figures 5H–5J).
A Computational Screen for Direct Genetic
Targets of Olig2
An oppositional relationship between growth and differen-
tiation is controlled by pRB, p53, and their downstream
effector proteins (Adams and Kaelin, 1998; Cheng et al.,508 Neuron 53, 503–517, February 15, 2007 ª2007 Elsevier Inc.2000; Kippin et al., 2005; Meletis et al., 2006). Olig2 is
known to function as a transcriptional repressor (Mizugu-
chi et al., 2001; Novitch et al., 2001). Using a strategy sum-
marized in Figure 6, we conducted a genome-wide com-
putational screen for Olig2 repressible genes that are
enriched for cis-acting E-box regulatory elements and
might function as components of the pRB or p53 signaling
networks.
Entry-level expression profiling data (Figure 6 and
Tables S1 and S2) showed, as expected, that Olig2 null
neurospheres lacked oligodendroglial lineage gene ex-
pression signatures (e.g., PDGFRa, PLP, MBP). Some
genes indicative of stem cell character (Ivanova et al.,
2002; Livesey et al., 2004; Parker et al., 2005; Ramalho-
Santos et al., 2002) were not significantly changed in
Olig2 null neurospheres relative to wild-type whereas
others, including prominin 1/CD133, were actually more
Neuron
Olig2 Is Required in Glioma ProgenitorsFigure 6. A Computational Screen for
Direct Genetic Targets of Olig2
The screen is predicated on the functions of
Olig2 protein as a transcriptional repressor
(Mizuguchi et al., 2001; Novitch et al., 2001)
that binds to canonical E-box regulatory ele-
ments of its target genes (Lee et al., 2005).
Microarray expression profiling identified 882
probe sets that were derepressed (upregu-
lated) in Olig2 null neural stem cells relative to
their wild-type counterparts (see Table S1).
An additional 1021 probe sets corresponded
to mRNAs that were downregulated in Olig2
null cells relative to wild-type (Table S2). The
list of derepressed probe sets was filtered
through the MAPPER tool for binding-site anal-
ysis to identified 167 genes with promoters en-
riched for E-box control elements. Analysis of
this list of potential Olig2 targets revealed the
presence of p21 and three additional p53-in-
ducible genes (see Table S3). A sampling of
marker genes for stem cells, oligodendrocytes,
astrocytes, and neurons that are either dere-
pressed (black font), repressed (red font), or
unchanged () in Olig2 null cells relative to
wild-type is shown.prevalent in the Olig2 null cells. Astrocyte-specific
markers were generally unaffected by Olig2 expression
with the exception of Gfap, which can mark both fibrous
astrocytes in the brain (Bignami et al., 1972) and neural
progenitor cells (Doetsch et al., 1999). Canonical neuronal
marker genes showed no apparent trend, with some
genes being upregulated and others downregulated in
the absence of Olig2 (Figure 6 and Tables S1 and S2).
Filtering the expression profiling data for Olig2-repress-
ible, E-box-enriched probe sets (Figure 6) identified four
p53-inducible genes (Figure 6 and Table S3). Three of
these p53-responsive genes are poorly characterized
from a functional perspective. However, the fourth is
p21WAF1/CIP1 (hereafter termed ‘‘p21’’), which encodes
a p53-inducible inhibitor of cell cycle progression. The
p21 gene product antagonizes phosphorylation of pRB
by inhibiting the activity of cyclin-dependent kinase 2
(Adams and Kaelin, 1998). We focused our subsequent
studies on the relationship between Olig2 and p21 be-Ncause targeted disruption of p21 has been shown to
enhance the proliferation of adult neural progenitor cells
(Kippin et al., 2005).
The Tumor Suppressor p21 Is a Direct Target
of Olig2 Repression in Normal Stem Cells
and Malignant Glioma
The activity of p21 is regulated primarily at the transcrip-
tional level through canonical E box DNA-binding ele-
ments in the upstream promoter/enhancer region of the
gene (Gartel and Radhakrishnan, 2005), leading to the hy-
pothesis that Olig2 might directly regulate p21 through
such sites (Figure 7A).
Quantitative PCR was used to validate the original ex-
pression profiling data implicating p21 as an Olig2 re-
pressible gene. As indicated in Figure 7B, p21 expression
is upregulated nearly 3-fold in Olig2 null neurosphere cells
relative to their wild-type counterparts. Moreover, in a hu-
man glioma cell line (U87), ectopic Olig2 suppresses theeuron 53, 503–517, February 15, 2007 ª2007 Elsevier Inc. 509
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Olig2 Is Required in Glioma ProgenitorsFigure. 7. p21 Is a Direct Target of Olig2 Repression in Neural Stem/Progenitor Cells and Human Glioblastoma
(A) Diagram of P21 promoter region. Arrowheads indicate promoter regions analyzed by PCR in ChIP assays. E boxes (red) and a p53 binding site
(blue) are shown within the region that is bound by Olig2 (red box).
(B) Quantitative PCR validates increased expression of p21 mRNA in Olig2 null (n = 6) versus wild-type (n = 3) neurospheres (p < 0.036).
(C) p21 luciferase reporter activity is repressed by Olig2 expression in a human GBM cell line (U87) while a dominant-negative Olig2 (dnOlig2) defec-
tive in binding DNA yields increased expression (p values < 0.0001).
(D) ChIP analysis using anti-Olig2 antibody to detect Olig2 binding to the p21 promoter in E14 rat cortical progenitor cells. Olig2 binding was only
detected upon induction of Olig2 expression by FGF. Input is total DNA.
(E) ChIP analysis of p21 promoter in a human glioma cell line transfected with a construct encoding a tamoxifen-activated Olig2 fusion protein. No
binding to the related cell cycle inhibitors p27 or p57 is detected. Olig2 is detected using anti-ER antibody.
(F) ChIP analysis demonstrating OLIG2 is bound to the p21 locus in vivo within freshly isolated human GBM specimens (n = 3, T1–T3). Mock ChIP was
conducted with normal rabbit IgG as control.
Error bars indicate SEM.expression of a p21/luciferase reporter construct (Fig-
ure 7B) while a dominant-negative Olig2 defective in bind-
ing DNA causes increased expression (p < 0.0001;
Figure 7C).
Chromatin immunoprecipitation (ChIP) assays show
that p21 is a direct genetic target of Olig2. For these as-
says, a variety of controls were used to exclude adventi-
tious interactions between Olig2 antibodies and the p21
gene. First, we took advantage of the fact that cortical pro-
genitor cells from E14 rat embryo do not express Olig2 un-
less they are exposed to FGF or Sonic hedgehog proteins
(Gabay et al., 2003; Kessaris et al., 2004). As shown
(Figure 7D), ChIP assays detect an FGF-dependent
Olig2/p21 interaction in these cortical progenitor cells.
Second, we transfected a tamoxifen-activated Olig2 fu-
sion protein into a human glioma cell line (HOG) that
does not express endogenous Olig2. Using ChIP assays,
we found that this ectopic Olig2 binds to human p21 reg-
ulatory elements in the presence of tamoxifen but not in its
absence (Figure 7E). Moreover, the ectopic Olig2 does not
interact with upstream regulatory elements of two other
p21-like CDK2 inhibitors, p27 and p57, that are regulated
primarily by posttranscriptional mechanisms (Agrawal
et al., 1996; Gartel and Radhakrishnan, 2005; Hengst
and Reed, 1996; Pagano et al., 1995; Figure 7F). Finally,
we used ChIP assays to show endogenous Olig2 interact-
ing with p21 regulatory elements in fresh surgical isolates510 Neuron 53, 503–517, February 15, 2007 ª2007 Elsevier Incof human malignant gliomas (glioblastoma) but not with
control IgG (Figure 7F). Collectively, these data show
that Olig2 interacts directly with upstream regulatory ele-
ments of p21 and functionally can repress its expression.
DISCUSSION
Genetic lesions that underlie malignant glioma in humans
include activating mutations in the EGFR and PI-3 kinase
pathways and loss-of-function mutations in tumor sup-
pressors such as p53 and p16INK4A/p19ARF (Barber
et al., 1997, 2004; Duerr et al., 1998; Rasheed et al.,
1997, 1999; Samuels et al., 2004; Steck et al., 1988). How-
ever, these mutations are not unique to cancers of the
CNS. Lineage-restricted pathways that regulate brain
tumor behavior may represent more specific therapeutic
targets with little potential to affect off-target cell types.
We show here that a stereotypic combination of mutant
EGFR and Ink4a/Arf loss, two genetic lesions commonly
found in primary gliomas in humans, can evidently only
cause brain tumors in the context of Olig2 function. In
both normal and malignant neural stem cells, Olig2 func-
tions as a direct repressor of the cell cycle inhibitor
gene, p21. Together, our findings demonstrate an Olig2-
regulated lineage-restricted pathway that is critical for
proliferation of normal and tumorigenic CNS stem cells..
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Olig2 Is Required in Glioma ProgenitorsOlig2 Expression Is a Unifying Feature of Normal
Stem Cells and Malignant Glioma
Analogies have been drawn between formation of blood
and development of the brain, a common underlying
theme being the replication-competent stem cell, which
occasionally divides asymmetrically to give rise to com-
mitted progenitor cells (Anderson, 2001). Recent evidence
indicates that the cell of origin for some leukemias resem-
bles in many respects normal hematopoietic progenitors
(Krivtsov et al., 2006). This observation and other data
support the emerging view that critical lineage-specific
determinates of cancer progenitor-cell growth may be
found in their normal developmental counterparts (Garr-
away and Sellers, 2006; Kho et al., 2004).
Although the cell of origin for malignant glioma remains
obscure (Kesari and Stiles, 2006; Sanai et al., 2005), re-
cent studies have highlighted similarities with multipotent
neural stem and progenitor cells found in the developing
and adult mammalian brain (Jackson et al., 2006). Highly
tumorigenic subpopulations of cells in malignant gliomas
have been identified that express the hematopoietic
stem cell marker CD133. As is true of normal progenitor
cells from the germinal zones of the embryonic and adult
CNS, these tumor stem cells can be cultured as self-
renewing ‘‘spheres’’ with multipotent characteristics
(Bao et al., 2006; Galli et al., 2004; Singh et al., 2003;
Yuan et al., 2004). In analogy to neural progenitor cells
of the adult brain (Sanai et al., 2005), malignant glial tu-
mors might be viewed as populations of (1) developmen-
tally uncommitted stem cells marked by CD133, (2) rapidly
cycling, transit-amplifying cells marked by Ki67 that con-
tribute significantly to tumor growth, and (3) CD133-nega-
tive, noncycling progeny cells that make up the bulk of the
tumor mass. We show here that all three of these tumor
cell populations contain cells that are positive for OLIG2.
Analogies can be drawn between the OLIG2 expression
pattern in glioma and in normal adult brains where expres-
sion is observed in (1) a subset of ‘‘type B’’ stem cells, (2) in
transit-amplifying (‘‘type C’’) progenitors of the subventric-
ular zone (Hack et al., 2005; Menn et al., 2006), and (3) in
terminally differentiated oligodendrocytes throughout the
brain. In preliminary studies (data not shown), we have
noted that not all of the CD133-positive cells in our clinical
specimens are positive also for Ki67. The mixture of Ki67-
positive and negative cancer stem cells might suggest
that the OLIG2-positive stem cells represent a transition
state between the B and the transit-amplifying C cell of
the normal brain.
Because it is expressed in three biologically distinct cell
cohorts, OLIG2 alone cannot serve as a specific marker
for any functional subset of glioma cells. However, the crit-
ical role of Olig2 in murine gliomagenesis provides incen-
tive to look for additional markers that could be used in
combinatorial fashion to resolve these functional subsets
in human cancers. A better resolution of the putative
stem cell population marked by CD133 would be of spe-
cial interest. Additional markers might also be used to bet-
ter define the relationship between glioma stem cells andNthe type B and type C cells within the germinal zone of the
adult brain.
An Olig2-Dependent Pathway Underlies Glioma
Formation and Regulates Growth of Normal Neural
Stem Cells
Both normal and tumorigenic progenitor cells share an
Olig2 requirement for growth. At what developmental
time point might such effects be relevant? Loss of Olig2
function in the embryonic forebrain ganglionic eminence
does not result in global changes to ventricular zone pro-
liferation or cell death. Rather, one observes a failure to
develop oligodendrocytes (Lu et al., 2002; Zhou and An-
derson, 2002) and subsets of neurons (Furusho et al.,
2006), suggesting primarily an early role in cell fate spec-
ification. However, sustained expression of Olig2 at adult
stages, in a subset of type B stem cells and transit-ampli-
fying (type C) progenitors (Menn et al., 2006) suggests
additional roles for this transcription factor in late-stage
proliferating progenitor cells found in the adult SVZ. We
further speculate that Olig2 could also serve cell cycle
regulatory roles in slowly replicating NG2 progenitor cells
that are abundant in the adult cerebral cortex (Ligon et al.,
2006).
To better understand the mechanisms critical for growth
of glioma, we focused on the proliferating subset of cells in
human GBM. Approximately 10%–15% of cells in these
tumors are actively dividing, and of these, we found that
85% expressed OLIG2. Both OLIG1 and OLIG2 are ex-
pressed in human glioma (Lu et al., 2001b; Marie et al.,
2001). However, our findings indicate that Olig2 function
in particular is necessary for tumorigenesis in a robust mu-
rine model of primary glioma that incorporates activation
of EGFR and mutation of the Ink4a/Arf locus. Interestingly,
similar findings are obtained when Olig2 is conditionally
deleted from an independent glioma model based on mu-
tations of the Nf1 and p53 loci (R. Lu and L. Parada, per-
sonal communication). Thus, the requirement for Olig2
function may apply to glioma formation in general.
Olig2 Functions as a ‘‘Gateway’’ Gene for Brain
Tumor Development
Olig2 fulfills criteria of a lineage-restricted competence
factor for brain cancer, and in this respect it bears striking
analogy to the bHLH-LZ transcription factor, MITF, in mel-
anoma (Du et al., 2004; Garraway and Sellers, 2006). First,
Olig2 function is crucial for the development of neural pro-
genitors and progeny cells specifically in the CNS. Sec-
ond, its expression is deregulated in brain cancer. Finally,
its function is required for tumor formation. However, the
notion of Olig2 as a critical lineage-restricted competence
factor for brain cancer does not depend on functions as an
oncogene per se. Although OLIG2 ectopic expression in
the T-cell lineage is associated with T-cell leukemia (Fer-
rando et al., 2004; Wang et al., 2000), gain-of-function
studies in mice suggest it is unlikely to be sufficient for
brain cancer formation (Lu et al., 2001a; K.L.L., E.H., and
D.H.R., unpublished data).euron 53, 503–517, February 15, 2007 ª2007 Elsevier Inc. 511
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specification of stem cells. We and others (Zhou and An-
derson, 2002) have noted that Olig1/2-null neurospheres
are capable of self-renewal and differentiation into two
of the three principal neural cell types. Expression of
stem cell marker genes is either unaffected in Olig2 null
neurospheres compared to controls or actually upregu-
lated in the Olig2 null cells (Figure 6 and Table S1). Olig2
is expressed in type B cells of the SVZ (Menn et al.,
2006) and CD133-positive cells in human glioma (this
study), and so it might regulate the transition from quies-
cent stem cell to transit-amplifying progenitor cell in the
context of normal development and tumorigenesis, re-
spectively.
Molecular Mechanisms of Olig2 Gateway Function
The p21 cell cycle inhibitor gene is notable for its important
role in maintaining the relatively quiescent state of stem
cells for both blood (Cheng et al., 2000) and brain (Kippin
et al., 2005). In addition, p53 regulation of neural stem cell
growth is also mediated in part through its effects on p21
(Meletis et al., 2006). Targeted disruption of p21 enhances
the proliferation rate of neural stem cells in the adult mam-
malian forebrain (Kippin et al., 2005). Our data show that
the p21 locus is subject to direct Olig2 transcriptional re-
pression, thus providing a direct link between Olig2 and
the cell cycle regulatory apparatus in normal and glioma-
genic progenitors. Collectively, these observations raise
the interesting possibility that OLIG2 function might be
dispensable for tumor formation in a p21 null context.
However, an alternative, more complex scenario is sug-
gested by our computational screen, which reveals three
additional p53-inducible genes that may serve as direct
genetic targets for Olig2 (Table S3). The p21 gene product
does function as a tumor suppressor in knockout mice but
its activity as such is rather weak. Moreover, p21 loss-of-
function mutations are infrequent in human cancers
(Adams and Kaelin, 1998; Gartel and Radhakrishnan,
2005). The laboratory and clinical data suggest that loss
of p53 gene function upstream of p21 is a far more effec-
tive route to cancer. Thus, OLIG2 might suppress multiple
p53 targets and/or other non-p53 target genes in its role
as a ‘‘gateway’’ gene for brain cancer.
Interestingly, primary glioblastomas are highly resistant
to radiation and cytotoxic drugs despite the fact that p53
is generally intact within these tumors. Although there are
multiple routes to suppression of p53 function (Besson
and Yong, 2001), our data suggest a novel, OLIG2-depen-
dent avenue to p53 pathway antagonism which is poten-
tially active even at early stages of gliomagenesis. One
might imagine that increased OLIG2 and decreased p21
expression would predict more aggressive tumor and
shorter survival times. However, the literature on p21
and glioma survival is ambivalent. Some studies show
that p21 expression is higher in low-grade than in high-
grade astrocytomas (Kamiya and Nakazato, 2002) and
that the presence of p21 is associated with prolonged sur-
vival (Korshunov et al., 2002). Other studies indicate that512 Neuron 53, 503–517, February 15, 2007 ª2007 Elsevier Inc.higher p21 staining is associated strongly with higher his-
tological grade (p < 0.001), a higher rate of proliferation
(p = 0.021), and worse survival (Miettinen et al., 2001). Still
other studies report that p21 levels have no impact at all
on survival in high-grade gliomas (Korshunov et al.,
2002; Kraus et al., 2001). There are many pitfalls to inter-
preting the impact of p21 (or any gene, for that matter)
on survival in gliomas. However, one obvious problem is
that previous studies have monitored p21 expression in
the whole tumor. It is conceivable that important prognos-
tic insights have been hitherto obscured for this reason. It
is possible that useful prognostic insights could be de-
rived from an analysis of p21 expression in CD133/
OLIG2-positive glioma cells.
We should also note that, in apparent contradistinction
to our findings, it has recently been reported that ectopic
OLIG2 expression retards growth of an immortalized gli-
oma cell line, binds to promoter elements of p27, and
stimulates expression of p27 mRNA and protein (Tabu
et al., 2006). These observations of a linkage between
OLIG2 and p27 gene transcription in a glioma cell line
stand apart from a wide range of data showing that p27
is regulated primarily by post transcriptional mechanisms
in other cell types (Agrawal et al., 1996; Gartel and Rad-
hakrishnan, 2005; Hengst and Reed, 1996; Pagano
et al., 1995). The p27 primers used for our ChIP assays
amplify in the region identified by Tabu et al., and yet we
did not detect any direct OLIG2:p27 interactions in pri-
mary human tumor samples. Further, p27 expression in
our OLIG2 null neurospheres was not altered. Some of
the discrepancies between the data reported here and
that of Tabu et al. may reflect the differential properties
of serum-cultured glioma cell lines versus primary neuro-
spheres and fresh human tumors that have been noted in
recent studies (Lee et al., 2006).
The Olig2-Regulated Lineage-Restricted Pathway: A
Potential Therapeutic Target in Brain Cancer
Brain tumors remain a major cause of cancer-related
death despite advances in surgery, imaging, and conven-
tional treatment modalities (Louis et al., 2002; Maher et al.,
2001). This emphasizes the need to develop novel medical
strategies based on a comprehensive understanding of
the biological mechanisms underlying gliomagenesis
(Rich and Bigner, 2004). Recent findings defining progres-
sion from normal progenitor to cancer stem cell in leuke-
mias have suggested that therapeutic targeting of a self-
renewal program expressed in an abnormal context may
be possible (Krivtsov et al., 2006). Identification of con-
served transcriptional regulatory mechanisms within nor-
mal and neoplastic hematopoietic progenitor cells has
facilitated diagnosis of acute myelogenous leukemia and
suggested novel therapeutic avenues (Tenen, 2003). In-
deed, recent studies have identified OLIG2 expression
as a negative prognostic indicator in human glioblastoma
(Liang et al., 2005), and our findings identify this core tran-
scriptional regulator as an important candidate for antitu-
mor therapeutics.
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Olig2 Is Required in Glioma ProgenitorsIn preliminary experiments, stem cells derived from a
primary human glioma were transduced with hairpin
RNAi expression vectors or dominant-negative mutation
constructs targeted toward OLIG2. Genetic knockdown
of OLIG2 by these means inhibited the ability of these hu-
man glioma stem cells to form intracranial tumors in SCID
mice (S.K. and C.D.S, unpublished data). Further experi-
ments with multiple human tumors are needed to compre-
hensively assess the requirement forOLIG2 function in the
settings of the various genetic lesions associated with hu-
man glioma such as PTEN, INK4a/ARF, and p53. While
transcription factors are not generally considered ‘‘dru-
gable’’ targets in antitumor therapy, OLIG2 activity could
be inhibited at the level of expression, posttranslational
modification, or protein-protein interactions (Kondo and
Raff, 2004; Setoguchi and Kondo, 2004; Sun et al.,
2003; Walensky et al., 2004). Equally, it should be possible
to define downstream factors in the Olig-regulated path-
way that could prove useful in this regard.
EXPERIMENTAL PROCEDURES
Mouse Procedures
Animal husbandry was performed according to DFCI ACUC approved
protocols for all experiments reported. Olig1-cre and Olig1/2 (Lu et al.,
2002; Zhou and Anderson, 2002) mouse lines were used on a mixed
Swiss and C57Bl6/J background. Ink4a/Arf mice were obtained from
the NCI mouse depository on a C57Bl6/J background. Immunocom-
promised Icr-SCID homozygous mice were obtained from Taconic
Inc. (model #ICRSC-M). For injections, neurospheres were dissociated
and resuspended in HBSS at a concentration of 100,000 viable cells/ml.
Two microliters were injected into the right striatum as previously
described (Bachoo et al., 2002). No effects of passage number were
noted for all cell lines injected. Animals were placed into survival or
time point cohorts and were sacrificed at the onset of neurological
symptoms or once moribund.
Neurosphere Cultures
Normal neural stem cells (NSC) were isolated from the ganglionic emi-
nences of E14.5 C57Bl6/J embryos, using techniques previously de-
scribed (Laywell et al., 2002). Cells were cultured in DMEM/F12 (with
L-Glutamine, Invitrogen) medium containing glucose (0.3%), penicillin/
streptomycin (50 mg/ml), Apo-Transferrin (0.1mg/ml), Progesterone
(20 nM), sodium selenite (30 nM), putrescine (60 mM), insulin (25 mg/ml),
and 20 ng/ml EGF (all reagents from Sigma). NSC were cultured on
plates coated with antiadhesive (Laywell et al., 2002), and neuro-
spheres were passaged once a week by mechanical dissociation.
Live cells were counted using a hemocytometer and Trypan blue
exclusion and replated at equivalent densities (2 3 104 cells/well) in
6-well plates.
Ink4a/Arf/EGFRvIII neurospheres were generated from various
genetic backgrounds using identical techniques. Ink4a/Arf/EGFRvIII
neurospheres were generated from Ink4a/Arf
/
NSCs (on Olig1/2+/ or
Olig1/2/ background). These cells were subsequently infected with
EGFRvIII encoding retrovirus at first passage (P1) and treated with
puromycin (2 mg/ml) 48 hr after infection. For the rescue experiment,
Ink4a/Arf/EGFRvIII neurospheres of various genetic backgrounds
were transduced with Olig2 or GFP encoding retroviruses at P3 and
selected with blasticidin (2 mg/ml). Expression of Olig2 or GFP was
confirmed by immunocytochemistry. Selection drugs were maintained
at all times during in vitro growth. Viable Ink4a/Arf/EGFRvIII cell
numbers at passage were generally higher for all genetic back-
grounds than normal neurospheres, and no changes in growth proper-Neties were noted up to 15 passages, including Olig1/2/ lines, which
showed partial growth deficiencies. Ink4a/Arf/EGFRvIII neuro-
spheres were injected at least two passages after last infection. No
difference in growth or tumor formation was noted upon testing of
frozen neurosphere lines (one heterozygous and one knockout line
tested).
Determination of neurosphere growth rates were performed by
counting the total viable cell numbers at time of passage over several
passages (from 4 to 10 passages) and averaged to calculate mean
cell number at passage. To estimate the number of proliferating cells,
neurospheres were pulsed with BrdU (1 mM) during the last 1 hr of
culturing, dissociated, and processed as previously described (Kippin
et al., 2005).
For Olig2 and BrdU immunostaining of neurosphere sections, neuro-
spheres were pulsed with 1 mM BrdU for 2 hr prior to fixation, washed in
PBS, and fixed in 4% PFA. Spheres were embedded in HistoGel
(Richard Allan Scientific), subsequently paraffin embedded, and
sectioned at 5 mm. Rabbit polyclonal anti-Olig2 (1/10,000) and mouse
monoclonal anti-BrdU (BD Biosciences; 1/100) were used in a stan-
dard immunohistochemistry protocol. All numbers are expressed as
mean ± SEM.
Retroviral Vectors and Virus Production
Construction of the retroviral vector encoding the constitutively active
mutant of EGFR (EGFRvIII) has been described (Bachoo et al., 2002).
Full-length mouse Olig2 was PCR cloned and an XbaI site added via
primer sequence to allow cloning into the EcoRI/XbaI sites of the
pWZL-BLAST retroviral vector (Morgenstern and Land, 1990). GFP
was similarly PCR cloned with primers that added EcoRI and XbaI sites
to the 50 and 30 ends, respectively.
Chromatin Immunoprecipitation
Chromatin immunoprecipitations were performed as described by
Shang et al. (2002) with the following modifications: for HOG cells sta-
bly transfected with Olig2-estrogen receptor fusion construct, tamox-
ifen (0.5 mM) was added for 4 hr prior to the crosslinking step. Rat cor-
tical progenitor cells were isolated from E14 embryos in serum-free
media as previously described (Williams et al., 1997). Proliferation
and Olig2 expression were induced by addition of fibroblast growth
factor 2 (30 ng/ml). After 4 days cells were processed for chromatin im-
munoprecipitation. Fresh surgical isolates of human glioblastoma
were snap frozen in liquid nitrogen. Frozen tissue was homogenized
and fixed with formaldehyde and processed for chromatin immuno-
precipitations.
The primers used for ChIP analysis were as follows: rat p21 F (for-
ward), AGGTGTCTAGACTCCAGATT, R (reverse) AAAATCAAGGCTTT
GCTGG (Olig2 binding region); human p21 SM19F TCCTGCAGCA
CGCGAGGTT, SM19R TGTGAGCAGCTGCCGAAGTC (219 to +7,
TATA box region); SM18F GGGCAGGAGGCAAAAGTCCT, SM18R
GAAGCCTGTCCTCCCCGAGG (1434 to 987, Olig2 binding re-
gion); SM17F GAACAGGGTATGTGATCTGC, SM17R TGGTACTGAG
CTTCACAATG (2137 to 1794, near p53 binding sites); and
SM29F TCTGTGAAAACATGCCCAGC, SM29R TTGAAACAGGGGAC
CGTGTC (4018 to 3732, far upstream region).
Luciferase Assay
The p21 promoter-luciferase reporter plasmid was constructed using
2.4 kB fragment from the upstream region containing Olig2 binding
sites in the human p21 promoter. The construct was cotransfected
with pcDNA3.1/myc/HIS-A, mouse Olig2 expression plasmid, or
mouse DN-Olig2 expression plasmid using Lipofectamine 2000 (Invi-
trogen) in U87 cells. Cells were harvested and assayed for luciferase
activity 2 days after transfection using a luciferase assay kit (Promega).
Luciferase activity for each construct was normalized using the protein
concentrations and analyzed using a Berthold Mithras LB940 plate-
reader for luminescence.uron 53, 503–517, February 15, 2007 ª2007 Elsevier Inc. 513
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RNA was extracted from neural progenitor cells using TRIzol reagent
(Invitrogen) and further purified using the RNeasy kit (Qiagen). One mi-
crogram of total RNA was used to generate cDNA, which was then
used for the quantitative PCR using premade TaqMan gene expres-
sion assays (Applied Biosystems) for p21 and rodent GAPDH.
Computational Screen for Olig2 Target Genes
The Affymetrix Mouse 430A2 microarray data of the murine Olig2-null
neural stem cells (four separate lines) were analyzed in comparison
with wild-type neural stem cells (three separate lines) using the non-
parametric wilcoxon ranksum test. A p value <0.05 was considered
significant. At this level of significance, there were 882 probe sets cor-
responding to genes that were overexpressed in Olig2-null cells rela-
tive to their wild-type counterparts. An additional 1021 probe sets cor-
responded to genes that were downregulated inOlig2 null cells relative
to wild-type cells. From the long list of 882 overexpressed probe sets,
we used the ‘‘MAPPER’’ search engine and database (Marinescu et al.,
2005a, 2005b) to identify 167 probe sets that contained an E-box motif.
Flow Cytometry
Dissected tissues from 11 independent cases of glioma were placed in
DMEM solution with antibiotics on ice until processing. Tissue was
washed in artificial cerebrospinal fluid (CSF) and acutely dissociated
as described previously (Singh et al., 2004) using a modified tissue dis-
sociation medium containing Collagenase IV (1 mg/ml; Worthington),
Hyaluronidase (0.67 mg/ml; Sigma), DNase I (0.4 mg/ml; Worthington),
kynurenic acid, and N-acetylcysteine (60 mg/ml; Sigma). Cells were
washed and used fresh for flow cytometry analysis or resuspended
in media for culture. Trypsin was avoided due to higher proteolytic ac-
tivity and potential cleavage of cell surface proteins (Anderson et al.,
2002). Red blood cells were removed using lympholyte-M (Cedarlane).
Fluorescent-activated cytometry was performed on a FACSCalibur
machine (BD Biosciences). Antibodies used included mouse IgG1
anti-CD133 antibody (AC133, unconjugated and PE- and APC-conju-
gated, Miltenyi Biotech), rabbit polyclonal Olig2 and Olig1 antibodies
(Arnett et al., 2004), mouse IgG1 and anti-Ki67 (M0722, Dako). Cells
were first stained for surface CD133 (antibody dilution 1:100) for 30
min at 4C then washed (PBS with 1% human serum), fixed, and per-
meabilized to allow access to intracellular antigens (Cytofix/Cytoperm
solution; BD Biosciences). Cells were then further incubated with anti-
body for intracellular antigens (dilution 1:100) for 30–90 min at 4C and
washed. Cells were incubated with secondary antibodies (anti-rabbit
Alexa 488 or Alexa 610-PE, and anti-mouse IgG Cy5 or Alexa 488,
Molecular Probes) for 30 min at 4C and washed twice before FACS
analysis. Single positives and isotype stains were used as controls
for compensation and gating thresholds. Data was analyzed using
FLOWJO software (v6.2.1; Tree Star, Inc).
Histology Analysis, Immunohistochemistry,
and In Situ Hybridization
Histological screening of tumors was performed by serial analysis of
H&E coronal sections taken at approximately 2 mm intervals along
the entire brain. Tumors were scored as present based on identifica-
tion of a collection of atypical cells greater than 2 mm in diameter,
although generally tumors at 2 months exceeded 1.5 cm in size and
infiltrated the entire right hemisphere. Selected animals that lacked
histologic evidence of tumors were also more stringently screened
for tumor growth by IHC for hEGFR.
Immunohistochemistry was performed according to standard proto-
cols (Ligon et al., 2004). A new monoclonal antibody to Olig2 was de-
veloped by standard methods. Polyclonal antibodies to Olig1 and
Olig2 were previously described (Arnett et al., 2004). Other antibodies
were Ki67 (rabbit polyclonal, Novocastra, Ki67p), p21 (mouse mono-
clonal, SantaCruz F5), NeuN (Chemicon), TuJ1 (Sigma), hEGFR
(Dako), Nestin (BD Biosciences), GFAP (Sigma), and BrdU (Chemicon).
In situ hybridization was performed on human tumors as previously de-514 Neuron 53, 503–517, February 15, 2007 ª2007 Elsevier Inscribed (Lu et al., 2001b) using full-length cDNA encoding human
CD133 (obtained from OpenBiosystems Inc.).
Collection and use of fresh and discarded human tumor tissue was
approved through Brigham and Women’s Hospital (BWH) Institutional
Review Board. After frozen section diagnosis of glioma by the attend-
ing neuropathologist, representative tissue samples were dissected.
Portions of the tumors were collected in chilled media for the studies
described here and other portions were allocated for paraffin embed-
ding for histological diagnosis.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/53/4/503/DC1/.
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